Key result
Β-Blocker administration reduced 5-year ischemia-driven target lesion revascularization compared to no β-blocker after everolimus-eluting stent implantation.
Why the study?
The effect of beta-adrenergic blockers on everolimus-eluting stent implantation outcomes remained unknown.
Does β-blocker administration reduce ischemia-driven target lesion revascularization in patients undergoing PCI with an everolimus-eluting stent?
Observational (n=1,899)
Does β-blocker administration reduce ischemia-driven target lesion revascularization in patients undergoing PCI with an everolimus-eluting stent?
Answers are grounded in this paper and cite their sources.
In patients undergoing PCI with everolimus-eluting stents, beta-blocker therapy is associated with a reduced risk of ischemia-driven target lesion revascularization at 5 years.
BACKGROUND/AIM: The effect of β-adrenergic blockers on everolimus-eluting stent (EES) implantation is unknown. We aimed to investigate how β-blockers affect the outcomes of EES by using the Tokyo-MD PCI registry data and analyse real-world data in this drug-eluting stent era in Japan. PATIENTS AND METHODS: We selected 1,899 patients who underwent EES implantation. We compared patients with β-blocker administration versus those without, at follow-up regarding the incidence rate of ischemia-driven target lesion revascularization (ID-TLR), all-cause death, cardiac death, acute myocardial infarction (AMI), and stent thrombosis (ST). RESULTS: Patients in the β-blocker group had higher coronary risks than those in the non-β-blocker group. Although no significant difference was observed in the five-year incidence of all-cause death, cardiac death, AMI, and ST between the two groups, the incidence of ID-TLR was significantly lower in the β-blocker group (4.5% vs. 6.6%; p=0.04). β-Blocker administration (hazard ratio=0.61; p=0.016) was negatively associated with ID-TLR via multivariate analysis. CONCLUSION: β-Blocker administration reduced ID-TLR after percutaneous coronary intervention using an EES despite the greater comorbid risks and more severe disease lesions.
No takes yet. Share an insight, caveat, or question.
Fujinami et al. (2021) conducted an observational in Percutaneous coronary intervention using an everolimus-eluting stent (n=1,899). β-blockers vs. No β-blocker administration was evaluated on Ischemia-driven target lesion revascularization (ID-TLR) (HR 0.61, p=0.016). Β-Blocker administration reduced 5-year ischemia-driven target lesion revascularization compared to no β-blocker after everolimus-eluting stent implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: